Epigenetic mechanisms of anti-fibrotic action for the liver
AssigneeUniversity of Southern California
InventorsHidekazu Tsukamoto, Clay Wang
Life of this patent
Estimating the term…
Abstract
This invention demonstrates the therapeutic efficacy of Yang-Gan-Wan (YGW) and its active components, especially in the formulation provided by Sheng-Pu Pharmaceutials, Inc., for treating and preventing liver fibrosis. This invention further demonstrates MeCP2 is an important therapeutic target for YGW and its active ingredients' action against liver fibrosis and cirrhosis.
Claims6
A method for treating and/or inhibiting liver fibrosis in a subject, comprising providing a therapeutically effective amount of a composition that inhibits or reduces epigenetic repression of Pparγ to the subject.
2-4. (canceled)
The method of claim1, wherein the composition reduces the level of MeCP2 expression in the subject.
8-15. (canceled)
Dependencies are inferred from the claim text.